BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1575 related articles for article (PubMed ID: 8141877)

  • 21. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
    Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent progress in the treatment of malignant lymphoma].
    Tobinai K; Shimoyama M
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1151-6. PubMed ID: 8031155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
    Zelenetz AD
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Hodgkin's lymphoma in Pakistan: a clinicopathological profile of 175 patients.
    Aziz Z; Rehman A; Akram M; Saeed A
    J Pak Med Assoc; 1999 Jan; 49(1):11-5. PubMed ID: 10463009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].
    Zhang C; Wang XP; Ying ZT; Zheng W; Xie Y; Lin NJ; Ping LY; Liu WP; Deng LJ; Song YQ; Zhu J
    Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2209-11. PubMed ID: 24169330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
    Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
    Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
    Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
    Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
    Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO
    J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
    Smalley RV; Andersen JW; Hawkins MJ; Bhide V; O'Connell MJ; Oken MM; Borden EC
    N Engl J Med; 1992 Nov; 327(19):1336-41. PubMed ID: 1406835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.
    Sarris AH; Braunschweig I; Medeiros LJ; Duvic M; Ha CS; Rodriguez MA; Hagemeister FB; McLaughlin P; Romaguera J; Cox J; Cabanillas F
    J Clin Oncol; 2001 Jan; 19(2):398-405. PubMed ID: 11208831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma.
    Solal-Celigny P; Chastang C; Herrera A; Desaint B; Renoux M; Gaulard P; Bernard JF; Brousse N; Boivin P
    Am J Med; 1987 Dec; 83(6):1075-9. PubMed ID: 3503575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
    J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
    Hasenclever D; Diehl V
    N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 79.